Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial

Dow Jones06-03

By Adriano Marchese

Arcus Biosciences has agreed to supply its investigational cancer-targeting drug to be evaluated in a Bristol Myers Squibb-sponsored trial in advanced kidney cancer.

The drug, casdatifan, will be added to two new arms of BMS's ROSETTA RCC-208 phase 1/2 study, which is testing pumitamig, an experimental two-in-one developed by BMS and BioNTech, both alone and in combination with other therapies to treat advanced renal cell carcinoma.

Each company keeps full rights to its own drug, and the collaboration is nonexclusive.

Arcus said that the collaboration is aimed at developing a new treatment approach that can keep kidney tumors under control for longer in a disease with few effective options.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

June 03, 2026 08:53 ET (12:53 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640904742?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 20:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640904742","market":"sg","top_or_hot":-1,"title":"Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences</a> has agreed to supply its investigational cancer-targeting drug to be evaluated in a Bristol Myers Squibb-sponsored trial in advanced kidney cancer. \n</p>\n<p>\n  The drug, casdatifan, will be added to two new arms of BMS's ROSETTA RCC-208 phase 1/2 study, which is testing pumitamig, an experimental two-in-one developed by BMS and BioNTech, both alone and in combination with other therapies to treat advanced renal cell carcinoma. \n</p>\n<p>\n  Each company keeps full rights to its own drug, and the collaboration is nonexclusive. \n</p>\n<p>\n  Arcus said that the collaboration is aimed at developing a new treatment approach that can keep kidney tumors under control for longer in a disease with few effective options. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2026 08:53 ET (12:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-03 20:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/RCUS\">Arcus Biosciences</a> has agreed to supply its investigational cancer-targeting drug to be evaluated in a Bristol Myers Squibb-sponsored trial in advanced kidney cancer. \n</p>\n<p>\n  The drug, casdatifan, will be added to two new arms of BMS's ROSETTA RCC-208 phase 1/2 study, which is testing pumitamig, an experimental two-in-one developed by BMS and BioNTech, both alone and in combination with other therapies to treat advanced renal cell carcinoma. \n</p>\n<p>\n  Each company keeps full rights to its own drug, and the collaboration is nonexclusive. \n</p>\n<p>\n  Arcus said that the collaboration is aimed at developing a new treatment approach that can keep kidney tumors under control for longer in a disease with few effective options. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2026 08:53 ET (12:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1323610961.USD","symbol_name":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640904742","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640904742","pubTimestamp":1780491180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Arcus Biosciences has agreed to supply its investigational cancer-targeting drug to be evaluated in a Bristol Myers Squibb-sponsored trial in advanced kidney cancer.The drug, casdatifan, will be added to two new arms of BMS's ROSETTA RCC-208 phase 1/2 study, which is testing pumitamig, an experimental two-in-one developed by BMS and BioNTech, both alone and in combination with other therapies to treat advanced renal cell carcinoma.Each company keeps full rights to its own drug, and the collaboration is nonexclusive.Arcus said that the collaboration is aimed at developing a new treatment approach that can keep kidney tumors under control for longer in a disease with few effective options.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4559":"巴菲特持仓","LU1032466523.USD":"高盛全球多资产收益组合Acc","BK4588":"碎股","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","RCUS":"Arcus Biosciences Inc.","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4007":"制药","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BMY":"施贵宝","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4532":"文艺复兴科技持仓","BK4581":"高盛持仓","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0237698245.USD":"富达环球地产基金A","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4139":"生物科技","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC"},"translate_title":"Arcus将为迈尔斯施贵宝试验提供实验性肾癌药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RCUS":0.9,"BMY":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\nArcus Biosciences has agreed to supply its investigational cancer-targeting drug to be evaluated in a Bristol Myers Squibb-sponsored trial in advanced kidney cancer. \n\n\n  The drug, casdatifan, will be added to two new arms of BMS's ROSETTA RCC-208 phase 1/2 study, which is testing pumitamig, an experimental two-in-one developed by BMS and BioNTech, both alone and in combination with other therapies to treat advanced renal cell carcinoma. \n\n\n  Each company keeps full rights to its own drug, and the collaboration is nonexclusive. \n\n\n  Arcus said that the collaboration is aimed at developing a new treatment approach that can keep kidney tumors under control for longer in a disease with few effective options. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2026 08:53 ET (12:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640904742","isCrawlerRequest":true}